A specific metabolic inhibitor (named ZY‐444) of pyruvate carboxylase (PC), the key anaplerosis enzyme, is discovered to exhibit cancer selectivity as well as great therapeutic efficacy against breast cancer progression. This evidence concerns the gene PC and breast carcinoma.